MedTrace Logo

Multiple Ascending Dose Study of MHS552 in Adults With Type 1 Diabetes Mellitus

NCT05272059 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-04-07

No results posted yet for this study

Summary

The purpose of this two-part multiple ascending dose study is to evaluate the safety and tolerability of multiple doses of MHS552 in adults with type 1 diabetes mellitus. Participants will be treated for 4 or 12 weeks followed by an 8 week follow-up period

Conditions

  • Type 1 Diabetes Mellitus

Interventions

DRUG

MHS552

MHS552 will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)

DRUG

Placebo

Placebo will be administered once weekly as subcutaneous injection for 4 (Part A) or 12 weeks (Part B)

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2025-04-14
Completion
2025-04-14

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05272059 on ClinicalTrials.gov